Synthesis of novel 2-(piperazino-1-yl-alkyl)-1H-benzimidazole derivates and assessment of their interactions with the D2 dopamine receptor

Jelena Z. Penjišević, Deana B. Andrić, Vladimir B. Šukalović, Goran M. Roglić, Vukić Šoškić, Slađana Kostić-Rajačić


A total of 14 novel arylpiperazines were synthesized, and pharmacologically
evaluated by measuring their affinities towards the D2 dopamine receptor
(DRD2) in a [3H]spiperone competition assay. All the herein described compounds
consist of a benzimidazole moiety connected to N-(2-methoxyphenyl)piperazine
via linkers of various lengths. Molecular docking analysis and molecular dynamics
simulations were performed on the DRD2–arylpiperazine complexes with the
objective of exploring the receptor–ligand interactions and properties of the receptor
binding site. The recently published crystal structure of DRD2 was used
throughout this study. The major finding is that high affinity arylpiperazines must
interact with both the orthosteric binding site and the extended binding pocket of
DRD2 and therefore should contain a linker of 5 or 6 methylene groups long.


arylpiperazines; molecular dynamics; molecular docking; receptor binding site


N. M. Urs, S. M. Peterson, M. G. Caron, Biol. Psychiatry 81 (2017) 78 (

J. M. Beaulieu, R. R. Gainetdinov, Pharmacological Reviews 63 (2011) 182 (

S. Reeves, E. McLachlan, J. Bertrand, F. D’Antonio, S. Brownings, A. Nair, S. Greaves, A. Smith, D. Taylor, J. Dunn, at al., Brain 140 (2017) 1117 (

S.M. Stahl, CNS Spectrums 22 (2017) 305 (

M. C. Lagerström, H. B. Schiöth, Nat. Rev. Drug Discov. 7 (2008) 339 (

J. P. Kesby, D. W. Eyles, J. J. McGrath, J. G. Scott, Transl. Psychiatry (2018) 8:30 (

E. Tomasella, L. Bechelli, M. B. Ogando, C. Mininni, M. N. Di Guilmi, F. De Fino, at al., Proc. Natl. Acad. Sci. 115 (2018) 3476 (

C. D. J. Kusters, K. C. Paul, I. Guella, J. M. Bronstein, J. S. Sinsheimer, M. J. Farrer, et al., Park. Relat. Disord. 47 (2018) 39 (

V. Soskic, V. Sukalovic, S. Kostic-Rajacic, Mini Rev. Med. Chem. 15 (2015) 988 (

X. Chen, M. F. Sassano, L. Zheng, V. Setola, M. Chen, X. Bai, at al., J. Med. Chem. 55 (2012) 7141 (

M. Marcinkowska, M. Kotańska, A. Zagórska, J’ Śniecikowska, M. Kubacka, A. Siwek at all , J. Enzyme Inhib. Med. Chem. 33 (2018) 536 (

G. Chłoń-Rzepa, A. Bucki, M. Kołaczkowski, A. Partyka, M. Jastrzębska-Więsek, G. Satała at all, J. Enzyme Inhib. Med. Chem. 31 (2016) 1048 (

H. Chen, F. Xu, X. Liang, B.B. Xu, Z. L. Yang, X.L. He, B.Y. Huang, M. Yuan, Bioorg. Med. Chem. Lett. 25 (2015) 285 (

M. Shaquiquzzaman, G. Verma, A. Marella, M. Akhter, W. Akhtar, M. F. Khan, S. Tasneem, M. M. Alam, Eur. J. Med. Chem. 102 (2015) 487 (

S. Wang, T. Che, A. Levit, B. K. Shoichet, D. Wacker, B. L. Roth, Nature 555 (2018) 269 (

H. Vogel, Drug Discovery and Evaluation – Pharmacological Assays, Springer, Berlin, Germany, 2002, p.501 ISBN: 978-3540423966

E. Therrien, P. Englebienne, A. G. Arrowsmith, R. Mendoza-Sanchez, C. R. Corbeil, N. Weill, et al., J. Chem. Inf. Model. 52 (2012) 210 (

RCSB PDB Protein Data Bank,, (accessed june 2018.)

D. A. Evans, Angew. Chemie Int. Ed. 53 (2014) 11140 (

Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018 Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2018

Orientations of Proteins in Membranes (OPM) database,, (accessed May 2018)

W. L. Jorgensen, J. Tirado-Rives, J. Am. Chem. Soc., 110 (1988) 1657 (

D. J. Evans, B. L. Holian, J. Chem. Phys. 83 (1998) 4069 (

G. J. Martyna, D. J. Tobias, M. L. Klein, J. Chem. Phys. 101 (1998) 4177 (

V. P. Vasić, J. Z. Penjišević, I. T. Novaković, V. V. Šukalović, D. B. Andrić, S. V. Kostić-Rajačić, J. Serb. Chem. Soc. 79 (2014) 277 (

D. Andrić, G. Roglić, V. Šukalović, V. Šoškić, S. Kostić-Rajačić, Eur. J. Med. Chem. 43 (2008) 1696 (

J. Z. Penjišević, V. V. Šukalović, D. B. Andrić, G. M. Roglić, I. T. Novaković, V. Šoškić, S. V. Kostić-Rajačić, J. Serb. Chem. Soc. 81 (2016) 347 (


Copyright (c) 2018 J. Serb. Chem. Soc.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

IMPACT FACTOR 0.828 (140 of 172 journals)
5 Year Impact Factor 0.917 (140 of 172 journals)